Next Article in Journal
Synthesis of Catechol Derived Rosamine Dyes and Their Reactivity toward Biogenic Amines
Next Article in Special Issue
Synthesis, In Silico and In Vitro Evaluation of Antimicrobial and Toxicity Features of New 4-[(4-Chlorophenyl)sulfonyl]benzoic Acid Derivatives
Previous Article in Journal
Olive Trees By-Products as Sources of Bioactive and Other Industrially Useful Compounds: A Systematic Review
Previous Article in Special Issue
Substituted Pyrazoles and Their Heteroannulated Analogs—Recent Syntheses and Biological Activities
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Molecules
Volume 26
Issue 16
10.3390/molecules26165083
molecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Synthesis of 3,5-Bis(trifluoromethyl)phenyl-Substituted Pyrazole Derivatives as Potent Growth Inhibitors of Drug-Resistant Bacteria

by
Ibrahim S. Alkhaibari
1,
Hansa Raj KC
1,
Subrata Roy
1,
Mohd. K. Abu-gazleh
1,
David F. Gilmore
2 and
Mohammad A. Alam
1,*
1
Department of Chemistry and Physics, The College of Sciences and Mathematics, Arkansas State University, Jonesboro, AR 72401, USA
2
Department of Biological Sciences, The College of Sciences and Mathematics, Arkansas State University, Jonesboro, AR 72401, USA
*
Author to whom correspondence should be addressed.
Molecules 2021, 26(16), 5083; https://doi.org/10.3390/molecules26165083
Submission received: 4 August 2021 / Revised: 19 August 2021 / Accepted: 19 August 2021 / Published: 22 August 2021
(This article belongs to the Special Issue Recent Advances in the Synthesis and Biological Studies of Five-Membered Azaheterocycle Derivatives)
Browse Figures
Review Reports Versions Notes

Abstract

:
Enterococci and methicillin-resistant S. aureus (MRSA) are among the menacing bacterial pathogens. Novel antibiotics are urgently needed to tackle these antibiotic-resistant bacterial infections. This article reports the design, synthesis, and antimicrobial studies of 30 novel pyrazole derivatives. Most of the synthesized compounds are potent growth inhibitors of planktonic Gram-positive bacteria with minimum inhibitory concertation (MIC) values as low as 0.25 µg/mL. Further studies led to the discovery of several lead compounds, which are bactericidal and potent against MRSA persisters. Compounds 11, 28, and 29 are potent against S. aureus biofilms with minimum biofilm eradication concentration (MBEC) values as low as 1 µg/mL.

Graphical Abstract

1. Introduction

Drug-resistant ESKAPE (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species) pathogens cause a majority of nosocomial infections all over the world. These multidrug-resistant bacteria have reduced treatment options, increased hospital stays and treatment costs, and amplified the death rate of infected patients [1]. E. faecium causes a variety of problems, including urinary tract, intra-abdominal, pelvic, and soft tissue infections, bacteremia, and endocarditis [2]. Approximately 30% of all healthcare-associated enterococcal infections are caused by E. faecalis and E. faecium, which are vancomycin-resistant (VRE), and these resistant strains are increasingly becoming resistant to other antibiotics. VRE is the most common cause of central line-associated bloodstream infections [3]. Furthermore, enterococcal biofilms cause 25% of all catheter-associated urinary tract infections [4]. Alcohol tolerance (ethanol and isopropanol) of clinical isolates of E. faecium has increased over the years, and isolates obtained after 2010 are 10-fold more tolerant to killing by alcohol than were older isolates [5]. S. aureus infections are caused by different strains, including methicillin-sensitive S. aureus (MSSA), methicillin-resistant S. aureus (MRSA), vancomycin-intermediate S. aureus (VISA), and vancomycin-resistant S. aureus (VRSA). Infections by MRSA are the most problematic, but any S. aureus infection can become serious [6]. MRSA causes ten-fold more infections than all multidrug-resistant (MDR) Gram-negative bacteria combined [7]. MRSA has emerged as one of the most menacing pathogens of humans, and this pathogen currently bypasses HIV in terms of fatality rate [8]. Hospitals are the hotbeds for highly drug-resistant pathogens, such as MRSA, increasing the risk of hospitalization kills instead of cures [9].
1H-Pyrazole (1,2-diazole) is a five-membered heterocycle, and its derivatives are known for a wide spectrum of biological activities [10]. It is found as the core structure of several leading drugs, such as celecoxib, a potent anti-inflammatory medicine [11]; tepoxalin, a nonsteroidal anti-inflammatory agent for veterinary use [10]; the anti-obesity drug, rimonabant [12]; the analgesic difenamizole [13]; and several other therapeutic agents. A number of drugs containing pyrazole nuclei may be due to its decreased susceptibility to oxidative degradation metabolism compared to other five-membered heterocycles [14]. Pyrazole derivatives have been reported as antimicrobial agents in several publications [15,16,17]. Although pyrazole derivatives as anti-MRSA agents have been reported by us [18,19,20,21,22] and others [23,24], pyrazole derivatives with anti-Acinetobacterial activity had not been reported until our recent papers [18,19,20,21,22].
The trifluoromethyl (–CF3) group strategically placed on a phenyl ring is known to improve the pharmacodynamics and pharmacokinetic properties of the resulting compounds [25]. A number of widely used drugs, such as dutasteride [26], hydroxyflutamide [27], and cinacalcet [28], contain the trifluoromethyl substituted phenyl moiety (Figure 1). We have found the trifluoromethyl substituted phenyl groups as potent growth inhibitors of different bacterial strains, including MRSA [22,29]. Based on the significance of the trifluoromethyl group in drug discovery, herein, we report the synthesis and antimicrobial activities of 3,5-bis(trifluoromethyl)phenyl substituted pyrazole derivatives as potent antimicrobial agents.

2. Results and Discussion

The designed compounds were synthesized by the reaction of 3′,5′-bis(trifluoromethyl)acetophenone (I) with 4-hydrazinobenzoic acid (II) to form the hydrazone intermediate, which on reaction with the Vilsmeier-Haack reagent formed the pyrazole aldehyde (III) [21,29,30,31]. This aldehyde intermediate (III) was synthesized on a 10 g scale, and the pure product was obtained simply by filtration and washing with water. Reductive amination of the aldehyde (III) with different anilines (R-NH2) formed the target compounds (1–30) in a very good average yield (Table 1). The synthetic method is very robust as different substituents on the aniline moiety did not affect the yield and purity of the products.
All the synthesized compounds were tested for their activity against Gram-positive and Gram-negative bacteria. These compounds showed broad activity against Gram-positive strains, but no activity against the Gram-negative strains (Table 2). The phenyl-substituted derivative (1) showed moderate activity against the tested bacteria with minimum inhibitory concentration (MIC) values as low as 2 µg/mL. Alkyl substitution on the phenyl ring of the aniline moiety increased the activity of the resultant compounds (2 and 3). 4-Isopropyl aniline derivative (2) inhibited the growth of S. aureus strains with MIC values in the range of 1 to 2 µg/mL. Similar potency was observed against Staphylococcus epidermidis, enterococci, and Bacillus subtilis strains. Methoxy substituent decreased the potency of the product (4) significantly. Activities of the compounds so far indicated that hydrophobic substituents on the phenyl ring increased the activity of the compounds. The phenoxy-substituted derivative was found to be a potent antimicrobial compound with MIC values of 1 µg/mL against several bacterial strains. The methyl sulfide attached compound (6) showed activity with MIC values in the range of 1 to 4 µg/mL. Fluorine substituted compounds (7 and 8) were good bacterial growth inhibitors. 3-Fluoro derivative (7) was found to be slightly less potent than the 4-fluoro derivative (8). Chloro-substitution resulted in a compound (9) with better activity than the fluoro derivatives. Bromo derivatives (10 and 11) are both potent antimicrobial agents, and the 4-chloro (9) showed similar antimicrobial activity. The carboxylic acid functional group eliminated the activity of the resultant compounds (12 and 13).
We found the disubstituted aniline derivatives as potent antibacterial compounds. Both methyl and halogen-substituted compounds (14, 15, and 16) showed MIC values as low as 1 µg/mL. 4-Bromo-3-methyl derivative (16) appeared the most potent compound among these three derivatives. Tested bacteria were less susceptible to the difluorophenyl-substituted compound (17) with MIC values 1–4 µg/mL across the tested strains. Chloro-fluoro substitution (18) showed better activity than the difluoro derivative (17). Dichloro aniline derivatives (19 and 20) were among the most potent compounds in the series, with MIC values as low as 0.5 µg/mL. 4-Bromo-3-chloro-aniline-substituted pyrazole derivative (21) was very effective with MIC values as low as 0.5 μg/mL against S. aureus, including MRSA strains. Tested enterococci strains were also inhibited efficiently by this compound (21) with the MIC values of 1 μg/mL. Trifluoromethyl derivatives (22 and 23) showed good activity across the tested strains. Trifluoro aniline derivatives (24 and 25) were comparatively less potent than other trisubstituted derivatives. All the mixed trihalo derivatives (26, 27, 28, and 29) showed good potency. Compound 26 inhibited the growth of many strains with MIC values as low as 0.25 μg/mL. The last compound (30) in the series was a good inhibitor of tested bacterial strains. The potency of most of the compounds was shown to be better than that of vancomycin and daptomycin, two widely used antibiotics to treat Gram-positive bacterial infections. Several compounds (e.g., 19, 20, 21, 22, 26, etc.) were up to 4 times more effective than these two positive controls against S. aureus strains. Some compounds (e.g., 3 and 19) were more potent than vancomycin and daptomycin against S. epidermidis bacterium. Most of the compounds were very potent against the enterococci strains compared to the positive controls.
Based on the activities, we found a good Structure Activity Relationship (SAR) of the product with respect to the substituents in the aniline moiety. The presence of a protic substituent, carboxylic acid, eliminated the activity of the compounds (12 and 13), which is in accordance with our previous findings [29,31,32]. The presence of lipophilic substituents (clog P = 7–8) on the phenyl ring of the aniline moiety increased the activity. As can be seen from the activity of mono-substituted compounds (2–11), the methoxy substituent is the least lipophilic (clog P = 6.63), and the corresponding compound (4) is the least potent for its antibacterial activity. Para isomers (8 and 11) are more potent than the corresponding meta products (7 and 10). Similar SAR was observed for disubstituted derivatives (14–23). Trisubstituted (24–29) and tetrasubstituted (30) compounds showed similar average activity as the disubstituted compounds.

2.1. Cytotoxicity Studies

After determining a high level of potency for several compounds, we tested them for their possible toxicity to cultured human cells (HEK-293) to select the least toxic compounds for further studies. Initially, compounds were tested at 50 and 25 µg/mL. Unfortunately, several compounds showed a toxic effect on HEK-293 cells. Compounds allowing >20% viability of HEK-293 cells at the tested concentrations were selected to test their toxicity at lower concentrations by determining their IC50 values (Figure 2). Compound 5 was the least toxic with an IC50 value of 9.15 µg/mL. Compounds 11, 28, and 29 inhibited the growth of these cells with IC50 values in the range of 7–8 µg/mL.

2.2. Time Kill Assay

Time Kill Assay studies give an idea of whether antibacterial agents are bactericidal or bacteriostatic. As can be seen in Figure 3, all four compounds were bactericidal, reducing bacterial concentrations 99.9% by 4 h and eliminating viable cells by 6 to 8 h. The positive controls, vancomycin (V) and daptomycin (D), eliminated >99.9% CFUs in 8 and 6 h, respectively. The negative control, DMSO, showed exponential growth as expected.

2.3. Activity against Persisters

Persisters are a nongrowing, antibiotic-tolerant state of bacteria. MRSA persisters are one of the major contributors to its virulence and lethality. Recently, a number of efforts are being made to eliminate MRSA persisters by using novel antibiotics [33,34,35]. In our effort to get potent anti-MRSA agents, we tested our promising compounds for their potency against persisters. Three of the four potent compounds (5, 11, 28, and 29) are very effective against S. aureus ATCC 700699 persisters. Compound 5 showed partial activity against the persisters (Figure 4). Compounds 11 and 29 were very effective at eliminating the persisters at 32× MIC value. Compared to the positive controls, these two compounds reduced the population of persisters by 4 log values. Compound 28 is also very effective against the persisters, but less potent than of compounds 11 and 29. Conventional antibiotics, vancomycin and daptomycin, failed to demonstrate persister kill activity at 32× MIC. Compounds 11 and 29 were further studied to examine the time-kill pattern during an 8 h period at various MIC concentrations (Figure 4b,c). Both compounds 11 and 29 eradicated more than 3 log values within an 8 h time course at all the 4× MIC, 8× MIC, and 16× MIC concentrations, demonstrating excellent bactericidal activity against MRSA persisters. The 2× MIC concentration of compound 11 eliminated 1 log value of the cells, while 2× MIC of compound 29 demonstrated almost 2 log values decrease of persister cells in 8 h time period. The level of detection in this experiment was 2 × 104 CFU/mL, and the data point on log10 4 in the graph was below the level of detection (Figure 4a–c).

2.4. Activity against S. aureus and E. faecalis Biofilms

Microbial biofilms are self-synthesized polymeric matrices that help microbial populations adhere to abiotic and biotic surfaces. Biofilms make bacteria recalcitrant to antibiotic treatment and protection from the host immune system. Biofilms formed by staphylococci (mostly by S. epidermidis and S. aureus) are the most common cause of device-related infections in hospital settings [7]. Enterococci biofilms are also frequently observed in the dysbiotic gastrointestinal tract, endocarditis, and wounds [4].
We tested the compounds showing potent activity against planktonic bacterial strains for their ability to eradicate the S. aureus and E. faecalis biofilms by using the Calgary Biofilm Device. As shown in Table 3, compound 11 showed potent antibiofilm property with the MBEC values 2 and 4 µg/mL against S. aureus and E. faecalis, respectively. Compounds 28 and 29 are even better with MBEC values that are as low as 1 µg/mL. Compound 5 did not show any appreciable biofilm eradication property. Comparing with the positive control, vancomycin (V) and daptomycin (D), our compounds (11, 28, and 29) are very potent in eradicating the S. aureus and E. faecalis biofilms.

3. Procedures

3.1. General Consideration

All of the reactions were carried out under an air atmosphere in round-bottom flasks. All reactant materials, solvents, deuterated solvents for 1H and 13C Nuclear Magnetic Resonance (NMR) spectroscopy, and for the reactions were purchased from Fisher Scientific (Hanover Park, IL, USA) and Oakwood chemical (Estill, SC, USA). 1H and 13C NMR spectra were recorded on a Varian Mercury with 300 MHz for 1H and 75 MHz for 13C NMR. The Fourier Transform Infrared (FTIR) spectra were obtained using 7 mm KBr pellets for the specimen using a Nicolet™ iS™ 10 FTIR spectrometer (Thermo Fisher Scientific Inc., Waltham, MA, USA). High Resolution Mass Spectrometry (HRMS) data were obtained by using the Brucker Apex II-FTMS system.

3.2. Synthesis of 3,5-Bis(trifluoromethyl)phenyl-derived Pyrazole Aldehyde (III)

4-Hydrazinobenzoic acid (1.597 g, 10.5 mmol) and 3,5-bis(trifluoromethyl)acetophenone (2.561 g, 10 mmol) were taken in a 100 mL round-bottom flask. Anhydrous ethanol (50 mL) was added to the flask, and the reaction mixture was refluxed for 8 h. After completing the reaction, the solvent was removed under reduced pressure using a rotary evaporator, resulting in a dry product. Then 30 mL anhydrous N,N-dimethylformamide (DMF) was added to the flask and sealed with a septum followed by stirring for 15 min to dissolve the compound. After getting a clear solution, the flask was cooled using an ice bath. Then phosphorous oxychloride, POCl3 (4.67 mL, 50 mmol) was added dropwise using a syringe through the septum. After 30 min, the mixture was brought to ambient temperature and heated at 90 °C for 8 h. Then, the reaction mixture was poured into an ice-full beaker (300 mL) and stirred for 10 h to make precipitate. The precipitate was filtered and washed with water several times. Drying under vacuum gave the final pure 3,5-bis(trifluoromethyl)phenyl-derived pyrazole aldehyde (III).

3.3. Synthesis of 3,5-Bis(trifluoromethyl)phenyl Substituted Pyrazole-Derived Anilines (1–30)

The pyrazole aldehyde (214.14 mg, 0.5 mmol) and 0.55 mmol aniline derivative were taken in a round-bottom flask and refluxed in toluene for 6 h in a Dean-Stark condenser. Then, the reaction mixture was cooled and filtered under vacuum. The precipitate was recrystallized in acetonitrile to give a pure imine product. The imine product (0.5 mmol) was dissolved in methanol and cooled to 0 °C using an ice bath. NaBH4 (94.5 mg, 2.5 mmol) was added to the solution before stirring the mixture for 10 h. After that 10% HCl was added to form the precipitate. The precipitate was recrystallized in acetonitrile to obtain the pure 3,5-bis(trifluoromethyl)phenyl substituted pyrazole-derived aniline product.

3.4. Compound Characterization Data

Molecules 26 05083 i032
4-[3-[3,5-Bis(trifluoromethyl)phenyl]-4-formyl-pyrazol-1-yl] benzoic acid (III). Beige solid; (420 mg, 98%); IR (KBr pellet, cm−1): 3095 (aromatic C-H), 2672, 1694 (C=O), 1608, 1131 (C-F); 1H NMR, 300 MHz (DMSO-d6): δ 9.96 (s, 1H, H-1), 9.58 (s, 1H, H-2), 8.70 (s, 2H, H-4), 8.21–8.11 (m, 5H, H-3, H-5 and H-6);13C NMR (75 MHz, DMSO-d6): δ 184.8, 166.9, 162.7, 149.3, 141.6, 138.7, 133.9 (3JC-F = 4.0 Hz), 131.4, 130.8 (2JC-F = 33.2 Hz), 129.4, 129.1, 123.7 (1JC-F = 270.6 Hz), 123.2, 119.5 (m). HRMS (ESI-FTMS Mass (m/z): calcd for C19H10F6N2O3 [M + H]+ = 429.0668, found 429.0747. (Supplementary Materials)
Molecules 26 05083 i033
4-[4-(Anilinomethyl)-3-[3,5-bis(trifluoromethyl)phenyl]pyrazol-1-yl] benzoic acid (1). Light beige solid; (436 mg, 86%); IR (KBr pellet, cm−1): 3415, 2894, 1699, 1608, 1360, 1316, 1278, 1174, 1134; 1H NMR, 300 MHz (DMSO-d6): δ 8.92 (s, 1H), 8.22 (s, 2H), 8.09–7.98 (m, 5H), 7.15 (d, J = 7.4 Hz, 2H), 7.00–6.92 (m, 3H), 4.45 (s, 2H); 13C NMR (75 MHz, DMSO-d6): δ 167.0, 149.8, 142.3, 135.0, 132.0, 131.5, 130.8 (2JC-F = 32.9 Hz), 130.3, 129.6, 129.3, 129.0, 128.5, 123.6 (1JC-F = 270.2 Hz), 122.1, 118.6, 116.4, 41.9. HRMS (ESI-FTMS Mass (m/z): calcd for C25H17F6N3O2 [M + H]+ = 506.1298, found 506.1291.
Molecules 26 05083 i034
4-[3-[3,5-Bis(trifluoromethyl)phenyl]-4-[(4-isopropylanilino)methyl]pyrazol-1-yl] benzoic acid (2). Light beige solid; (443 mg, 80%); IR (KBr pellet, cm−1): 3411, 2969, 1714, 1607, 1358, 1281, 1172, 1127; 1H NMR, 300 MHz (DMSO-d6): δ 8.92 (s, 1H), 8.31 (s, 2H), 8.06 (t, J = 8.7 Hz, 5H), 7.08 (d, J = 8.0 Hz, 2H), 6.94 (br, 2H), 4.48 (s, 2H), 2.75–2.73 (m, 1H), 1.11 (d, J = 6.7 Hz, 6H); 13C NMR (75 MHz, DMSO-d6): δ 167.0, 149.5, 142.3, 135.1, 132.1, 131.6, 131.0 (2JC-F = 32.8 Hz), 130.4, 129.3, 129.0, 128.4, 127.4, 123.6 (1JC-F = 271.2 Hz), 122.1, 118.6, 118.2, 43.0, 33.1, 24.1. HRMS (ESI-FTMS Mass (m/z): calcd for C28H23F6N3O2 [M + H]+ = 548.1767, found 548.1761.
Molecules 26 05083 i035
4-[3-[3,5-Bis(trifluoromethyl)phenyl]-4-[(4-tert-butylanilino)methyl]pyrazol-1-yl] benzoic acid (3). White solid; (526 mg, 93%); IR (KBr pellet, cm−1): 3419, 2969, 1712, 1607, 1357, 1281, 1178, 1131; 1H NMR, 300 MHz (DMSO-d6): δ 8.92 (s, 1H), 8.32 (s, 2H), 8.06 (t, J = 8.4 Hz, 5H), 7.23 (d, J = 8.0 Hz, 2H), 6.95 (d, J = 7.3 Hz, 2H), 4.49 (s, 2H), 1.18 (s, 9H); 13C NMR (75 MHz, DMSO-d6): δ 167.0, 149.5, 142.3, 135.1, 132.2, 131.6, 131.2, 130.8 (2JC-F = 32.6 Hz), 130.4, 129.4, 128.3, 126.4, 123.6 (1JC-F = 271.2 Hz), 122.2, 118.6, 118.2, 43.0, 34.4, 31.4. HRMS (ESI-FTMS Mass (m/z): calcd for C29H25F6N3O2 [M + H]+ = 562.1924, found 562.1919.
Molecules 26 05083 i036
4-[3-[3,5-Bis(trifluoromethyl)phenyl]-4-[(4-methoxyanilino)methyl]pyrazol-1-yl] benzoic acid (4). Light grey solid; (417 mg, 77%); IR (KBr pellet, cm−1): 3219, 2261, 1701, 1608, 1280, 1074, 1032; 1H NMR, 300 MHz (DMSO-d6): δ 9.03 (s, 1H), 8.09 (t, J = 9.3 Hz, 5H), 7.99 (d, J = 8.4 Hz, 2H), 7.11 (d, J = 8.4 Hz, 2H), 6.72 (d, J = 8.5 Hz, 2H), 4.59 (s, 2H), 3.63 (s, 3H); 13C NMR (75 MHz, DMSO-d6): δ 166.9, 150.4, 142.2, 134.8, 133.1, 131.6, 130.6 (2JC-F = 32.7 Hz), 129.5, 129.0, 128.7, 124.9, 123.6 (1JC-F = 271.2 Hz), 118.7, 118.1, 115.2, 114.7, 55.5, 44.6. HRMS (ESI-FTMS Mass (m/z): calcd for C26H19F6N3O3 [M + H]+ = 536.1403, found 536.1397.
Molecules 26 05083 i037
4-[3-[3,5-Bis(trifluoromethyl)phenyl]-4-[(4-phenoxyanilino)methyl]pyrazol-1-yl] benzoic acid (5). Off white solid; (477 mg, 79%); IR (KBr pellet, cm−1): 3416, 2749, 1692, 1607, 1313, 1179, 1140; 1H NMR, 300 MHz (DMSO-d6): δ 8.95 (s, 1H), 8.32 (s, 2H), 8.14–8.03 (m, 5H), 7.34 (t, J = 7.4 Hz, 2H), 7.11–7.01 (m, 3H), 6.88 (t, J = 7.6 Hz, 4H), 4.47 (s, 2H); 13C NMR (75 MHz, DMSO-d6): δ 167.0, 157.7, 149.6, 142.3, 135.1, 132.0, 131.5, 131.1 (2JC-F = 32.7 Hz), 130.3, 129.3, 128.6, 128.4, 125.5, 123.6 (1JC-F = 271.2 Hz), 123.4, 122.1, 120.3, 119.8, 119.4 118.6, 118.1. HRMS (ESI-FTMS Mass (m/z): calcd for C31H21F6N3O3 [M + H]+ = 598.1560, found 598.1556.
Molecules 26 05083 i038
4-[3-[3,5-Bis(trifluoromethyl)phenyl]-4-[(4-methylsulfanylanilino)methyl]pyrazol-1-yl] benzoic acid (6). Light yellow solid; (389 mg, 70%); IR (KBr pellet, cm−1): 3412, 2924, 1701, 1608, 1359, 1281, 1177, 1131; 1H NMR, 300 MHz (DMSO-d6): δ 8.93 (s, 1H), 8.29 (s, 2H), 8.12–8.02 (m, 5H), 7.10 (d, J = 8.5 Hz, 2H), 6.91 (d, J = 8.3 Hz, 2H), 4.44 (s, 2H), 2.36 (s, 3H); 13C NMR (75 MHz, DMSO-d6): δ 167.0, 149.3, 142.4, 135.2, 131.5, 130.9 (2JC-F = 32.8 Hz), 129.4, 129.2, 129.0, 128.2, 127.2, 124.2, 123.6 (1JC-F = 271.3 Hz), 122.1, 119.5, 118.5, 118.2, 17.2. HRMS (ESI-FTMS Mass (m/z): calcd for C26H19F6N3O2S [M + H]+ = 552.1175, found 552.1173.
Molecules 26 05083 i039
4-[3-[3,5-Bis(trifluoromethyl)phenyl]-4-[(3-fluoroanilino)methyl]pyrazol-1-yl] benzoic acid (7). White solid; (433 mg, 82%); IR (KBr pellet, cm−1): 3420, 2903, 1699, 1608, 1359, 1281, 1175, 1134; 1H NMR, 300 MHz (DMSO-d6): δ 8.84 (s, 1H), 8.40 (s, 2H), 8.07–8.11 (m, 5H), 7.10 (d, J = 7.05 Hz, 1H), 6.50 (t, J = 7.4 Hz, 2H), 6.38–6.29 (m, 1H), 4.29 (s, 2H); 13C NMR (75 MHz, DMSO-d6): δ 167.0, 163.7 (d, 1JC-F = 238.4 Hz), 150.2 (d, 3JC-F = 10.9 Hz), 148.9, 142.4, 135.3, 131.4 (3JC-F = 4.6 Hz), 131.0, 130.7 (d, 3JC-F = 10.2 Hz), 129.1, 127.9, 123.6 (1JC-F = 271.2 Hz), 122.0, 119.9, 118.4, 109.5, 103.4 (d, 2JC-F = 20.8 Hz), 99.4 (d, 2JC-F = 24.8 Hz), 38.3. HRMS (ESI-FTMS Mass (m/z): calcd for C25H16F7N3O2 [M + H]+ = 524.1204, found 524.1208.
Molecules 26 05083 i040
4-[3-[3,5-Bis(trifluoromethyl)phenyl]-4-[(4-fluoroanilino)methyl]pyrazol-1-yl] benzoic acid (8). Off white solid; (443 mg, 84%); IR (KBr pellet, cm−1): 3413, 2970, 1712, 1607, 1357, 1281, 1178, 1131; 1H NMR, 300 MHz (DMSO-d6): δ 8.92 (s, 1H), 8.26 (s, 2H), 8.09–8.04 (m, 5H), 6.99 (d, J = 6.7 Hz, 4H), 4.44 (s, 2H); 13C NMR (75 MHz, DMSO-d6): δ 167.0, 158.3 (d, 1JC-F = 236.5 Hz), 149.7, 142.3, 138.8, 135.0, 132.0, 131.7, 131.0 (2JC-F = 32.8 Hz), 129.3, 128.4, 125.4, 121.9 (d, 2JC-F = 21.5 Hz), 121.4 (1JC-F = 280.7 Hz), 118.6, 116.2 (d, 2JC-F = 22.4 Hz), 41.6. HRMS (ESI-FTMS Mass (m/z): calcd for C25H16F7N3O2 [M + H]+ = 524.1204, found 524.1200.
Molecules 26 05083 i041
4-[3-[3,5-Bis(trifluoromethyl)phenyl]-4-[(4-chloroanilino)methyl]pyrazol-1-yl] benzoic acid (9). Yellowish white solid; (391 mg, 72%); IR (KBr pellet, cm−1): 3409, 2899, 1699, 1608, 1359, 1286, 1178, 1130; 1H NMR, 300 MHz (DMSO-d6): δ 8.84 (s, 1H), 8.39 (s, 2H), 8.12–8.07 (m, 5H), 7.13 (d, J = 8.4 Hz, 2H), 6.73 (d, J = 8.6 Hz, 2H), 4.29 (s, 2H); 13C NMR (75 MHz, DMSO-d6): δ167.0, 149.0, 146.5, 142.4, 135.3, 131.4 (3JC-F = 7.1 Hz), 130.8 (2JC-F = 42.8 Hz), 129.1 (m), 128.0, 123.6 (1JC-F = 271.1 Hz), 123.2, 122.0, 121.3, 119.7, 118.5, 118.2, 115.1, 38.7. HRMS (ESI-FTMS Mass (m/z): calcd for C25H16ClF6N3O2 [M + H]+ = 540.0908, 542.0881, found 540.0907.
Molecules 26 05083 i042
4-[3-[3,5-Bis(trifluoromethyl)phenyl]-4-[(3-bromoanilino)methyl]pyrazol-1-yl] benzoic acid (10). Off white solid; (497 mg, 85%); IR (KBr pellet, cm−1): 3410, 3126, 1706, 1607, 1373, 1277, 1188, 1137; 1H NMR, 300 MHz (DMSO-d6): δ 8.85 (s, 1H), 8.40 (s, 2H), 8.13–8.08 (m, 5H), 7.03 (t, J = 7.8 Hz, 1H), 6.86 (s, 1H), 6.73 (dd, J = 7.8, 14.5 Hz, 2H), 4.29 (s, 2H); 13C NMR (75 MHz, DMSO-d6): δ 167.0, 149.8, 148.9, 142.4, 135.3, 131.8, 131.5, 130.9, 130.5, 129.1, 127.9, 123.6 (1JC-F = 271.1 Hz), 122.7, 122.0, 119.7 (2JC-F = 26.2 Hz), 118.4, 115.2, 112.1, 38.1. HRMS (ESI-FTMS Mass (m/z): calcd for C25H16BrF6N3O2 [M + H]+ = 584.0403, 586.0384, found 584.0410.
Molecules 26 05083 i043
4-[3-[3,5-Bis(trifluoromethyl)phenyl]-4-[(4-bromoanilino)methyl]pyrazol-1-yl] benzoic acid (11). Yellow solid; (457 mg, 78%); IR (KBr pellet, cm−1): 3377,3072, 1712,1607, 1356,1282,1178, 1128; 1H NMR, 300 MHz (DMSO-d6): δ 8.83 (s, 1H), 8.40 (s, 2H), 8.12–8.04 (m, 5H), 7.24 (d, J = 8.6 Hz, 2H), 6.67 (d, J = 8.7 Hz, 2H), 4.27 (s, 2H); 13C NMR (75 MHz, DMSO-d6): δ 167.0, 149.0, 147.2, 142.4, 135.3, 131.6 (2JC-F = 34.7 Hz), 131.0 (3JC-F = 4.0 Hz), 130.5, 129.1, 127.9, 123.6 (1JC-F = 271.2 Hz), 123.2, 122.0, 119.8, 118.4, 115.4, 108.4, 38.5. HRMS (ESI-FTMS Mass (m/z): calcd for C25H16BrF6N3O2 [M + H]+ = 584.0403, 586.0384, found 584.0408.
Molecules 26 05083 i044
3-[[3-[3,5-Bis(trifluoromethyl)phenyl]-1-(4-carboxyphenyl)pyrazol-4-yl]methylamino] benzoic acid (12). Light gold solid; (458 mg, 83%); IR (KBr pellet, cm−1): 3361, 3064, 1685, 1604, 1520, 1176, 1132; 1H NMR, 300 MHz (DMSO-d6): δ 8.84 (s, 1H), 8.43 (s, 2H), 8.12–8.08 (m, 5H), 7.28–7.20 (m, 3H), 6.92 (s, 1H), 6.33 (br, 1H), 4.32 (s, 2H); 13C NMR (75 MHz, DMSO-d6): δ 168.3, 167.0, 148.9, 148.6, 142.4, 135.3, 131.8, 131.4 (3JC-F = 4.5 Hz), 130.8 (2JC-F = 32.7 Hz), 129.4, 129.0, 127.9, 123.6 (1JC-F = 271.2 Hz), 122.0, 120.3, 118.4, 118.2, 118.0, 116.9, 113.5, 38.2. HRMS (ESI-FTMS Mass (m/z): calcd for C26H17F6N3O4 [M + H]+ = 550.1196, found 550.1194.
Molecules 26 05083 i045
4-[[3-[3,5-Bis(trifluoromethyl)phenyl]-1-(4-carboxyphenyl)pyrazol-4-yl]methylamino] benzoic acid (13). Light yellow solid; (451 mg, 82%); IR (KBr pellet, cm−1): 3361, 2667, 1686,1601,1419, 1282, 1178; 1H NMR, 300 MHz (DMSO-d6): δ 8.84 (s, 1H), 8.39 (s, 2H), 8.13–8.08 (m, 5H), 7.71 (d, J = 7.1 Hz, 2H), 6.83 (s, 1H), 6.70 (d, J = 8.6 Hz, 2H), 4.36 (s, 2H); 13C NMR (75 MHz, DMSO-d6): δ 167.9, 167.0, 152.3, 148.9, 142.4, 135.3, 132.8, 131.5 (3JC-F = 4.2 Hz), 130.8 (2JC-F = 32.5 Hz), 129.1, 129.0, 127.9, 123.6 (1JC-F = 271.2 Hz), 122.1, 119.9, 118.5, 118.2, 111.7, 37.7. HRMS (ESI-FTMS Mass (m/z): calcd for C26H17F6N3O4 [M + H]+ = 550.1196, found 550.1197.
Molecules 26 05083 i046
4-[3-[3,5-Bis(trifluoromethyl)phenyl]-4-[(4-fluoro-3-methyl-anilino)methyl]pyrazol-1-yl] benzoic acid (14). White solid; (497 mg, 92%); IR (KBr pellet, cm−1): 3424, 2906, 1698, 1608, 1358, 1281, 1177, 1139; 1H NMR, 300 MHz (DMSO-d6): δ 8.94 (s, 1H), 8.21 (s, 2H), 8.05 (t, J = 8.6 Hz, 5H), 6.94–6.83 (m, 3H), 4.48 (s, 2H), 2.04 (s, 3H); 13C NMR (75 MHz, DMSO-d6): δ 167.0, 158.3 (1JC-F = 240.57 Hz), 150.0, 142.3, 134.9, 132.4, 131.5, 130.7 (2JC-F = 32.7 Hz), 130.3, 129.4, 128.5, 125.6, 123.6 (1JC-F = 271.11 Hz), 122.1, 118.6, 118.1, 115.9 (d, 2JC-F = 23.5 Hz), 39.0, 14.5. HRMS (ESI-FTMS Mass (m/z): calcd for C26H18F7N3O2 [M + H]+ = 538.1360, found 538.1356.
Molecules 26 05083 i047
4-[3-[3,5-Bis(trifluoromethyl)phenyl]-4-[(3-chloro-4-methyl-anilino)methyl]pyrazol-1-yl] benzoic acid (15). Light brown solid; (453 mg, 81%); IR (KBr pellet, cm−1): 3366, 2930, 1724, 1608, 1405, 1277, 1177, 1128; 1H NMR, 300 MHz (DMSO-d6): δ 8.93 (s, 1H), 8.26 (s, 2H), 8.08–7.99 (m, 5H), 7.07 (d, J = 8.2 Hz, 1H), 6.95 (s, 1H), 6.80 (d, J = 8.0 Hz, 1H), 4.39 (s, 2H), 2.12 (s, 3H); 13C NMR (75 MHz, DMSO-d6): δ 166.9, 149.4, 142.3, 135.0, 133.8, 132.0, 131.8, 131.5, 130.8 (2JC-F = 32.7 Hz), 129.2, 129.0, 128.2, 123.6 (1JC-F = 271.1 Hz), 121.9, 118.5, 118.1, 117.5, 117.0, 116.6, 19.0. HRMS (ESI-FTMS Mass (m/z): calcd for C26H18F6N3O2Cl [M + H]+ = 554.1065, 556.1037, found 554.1065.
Molecules 26 05083 i048
4-[3-[3,5-Bis(trifluoromethyl)phenyl]-4-[(4-bromo-3-methyl-anilino)methyl]pyrazol-1-yl] benzoic acid (16). Yellowish white solid; (489 mg, 82%); IR (KBr pellet, cm−1): 2930, 1683, 1607, 1355, 1277, 1134; 1H NMR, 300 MHz (DMSO-d6): δ 8.84 (s, 1H), 8.25 (s, 2H), 8.03–7.99 (m, 5H), 7.24 (d, J = 8.5 Hz, 1H), 6.80 (s, 1H), 6.61 (d, J = 7.9 Hz, 1H), 4.33 (s, 2H), 2.12 (s, 3H); 13C NMR (75 MHz, DMSO-d6): δ 167.0, 149.3, 143.8, 142.3, 138.0, 135.1, 132.8, 131.7, 131.4, 130.8 (2JC-F = 32.7 Hz),129.2, 129.0, 128.1, 123.5 (1JC-F = 271.2 Hz), 118.8, 118.4, 118.1, 117.7, 116.2, 22.9. HRMS (ESI-FTMS Mass (m/z): calcd for C26H18BrF6N3O2 [M + H]+ = 598.0559, 600.0540, found 598.0553.
Molecules 26 05083 i049
4-[3-[3,5-Bis(trifluoromethyl)phenyl]-4-[(3,4-difluoroanilino)methyl]pyrazol-1-yl] benzoic acid (17). White solid; (449 mg, 83%); IR (KBr pellet, cm−1): 3412, 2802, 1701, 1608, 1358, 1281, 1174, 1139; 1H NMR, 300 MHz (DMSO-d6): δ 8.83 (s, 1H), 8.35 (s, 2H), 8.08–8.05 (m, 5H), 7.19–7.09 (m, 1H), 6.74–6.71 (m, 1H), 6.51 (d, J = 6.6 Hz, 1H), 4.26 (s, 2H); 13C NMR (75 MHz, DMSO-d6): δ 167.0, 150.3 (dd, JC-F = 13.1, 233.8 Hz), 149.0, 144.9 (d, 3JC-F = 8.5 Hz), 142.5 (dd, JC-F = 13.0, 239.0 Hz), 142.4, 135.2, 131.8, 131.4 (3JC-F = 5.3 Hz), 130.8 (2JC-F = 32.6 Hz), 129.1, 127.9, 123.6 (1JC-F = 271.2 Hz), 123.2, 121.9, 119.3, 118.4, 117.9 (d, 2JC-F = 17.4 Hz), 109.7, 102.0 (d, 2JC-F = 20.2 Hz). HRMS (ESI-FTMS Mass (m/z): calcd for C25H15F8N3O2 [M + H]+ = 542.1109, found 542.1122.
Molecules 26 05083 i050
4-[3-[3,5-Bis(trifluoromethyl)phenyl]-4-[(3-chloro-4-fluoro-anilino)methyl]pyrazol-1-yl] benzoic acid (18). Off white solid (506 mg, 90%); IR (KBr pellet, cm−1): 3412, 2898, 1698, 1608, 1356, 1278, 1177, 1142. 1H NMR, 300 MHz (DMSO-d6): δ 8.85 (s, 1H), 8.34 (s, 2H), 8.09–8.05 (m, 5H), 7.14 (t, J = 9.0 Hz, 1H), 6.88 (s, 1H), 6.71 (d, J = 8.8 Hz, 1H), 4.29 (s, 2H); 13C NMR (75 MHz, DMSO-d6): δ 167.0, 150.8 (d, 1JC-F = 235.0 Hz), 149.1, 144.3, 142.4, 135.2, 131.8, 131.4, 131.2 (2JC-F = 32.7 Hz), 130.5, 129.1 (d, 3JC-F = 10.5 Hz), 128.0, 123.6 (1JC-F = 271.2 Hz), 122.0, 119.9 (d, 2JC-F = 18.1 Hz), 119.0, 118.4, 117.4 (d, 2JC-F = 21.4 Hz), 114.8. HRMS (ESI-FTMS Mass (m/z): calcd for C25H15ClF7N3O2 [M + H]+ = 558.0814, 560.0786, found 558.0816.
Molecules 26 05083 i051
4-[3-[3,5-Bis(trifluoromethyl)phenyl]-4-[(3,4-dichloroanilino)methyl]pyrazol-1-yl] benzoic acid (19). Off white solid; (497 mg, 86%); IR (KBr pellet, cm−1): 3403, 2866, 1682, 1607, 1359, 1278, 1143; 1H NMR, 300 MHz (DMSO-d6): δ 8.83 (s, 1H), 8.39 (s, 2H), 8.14–8.08 (m, 5H), 7.29 (d, J = 8.7 Hz, 1H), 6.88–6.87 (m, 1H), 6.66 (dd, J = 2.5, 8.82 Hz, 1H), 6.54–6.52 (m, 1H), 4.31–2.29 (m, 2H); 13C NMR (75 MHz, DMSO-d6): δ 167.0, 152.3, 148.8, 148.3, 146.1, 142.4, 135.2, 131.4, 130.7 (2JC-F = 35.3 Hz), 129.0, 127.8, 123.6 (1JC-F = 266.3 Hz), 120.0 (3JC-F = 5.9 Hz), 119.7, 118.3, 117.4, 117.1, 113.0, 112.6 (m), 38.4. HRMS (ESI-FTMS Mass (m/z): calcd for C25H15Cl2F6N3O2 [M + H]+ = 574.0518, 576.0490, found 574.0776.
Molecules 26 05083 i052
4-[3-[3,5-Bis(trifluoromethyl)phenyl]-4-[(3,5-dichloroanilino)methyl]pyrazol-1-yl] benzoic acid (20). Off white solid; (489 mg, 85%); IR (KBr pellet, cm−1): 3425, 3090, 1697, 1607, 1362, 1281, 1186, 1138; 1H NMR, 300 MHz (DMSO-d6): δ 8.82 (s, 1H), 8.36 (s, 2H), 8.12–8.07 (m, 5H), 6.67 (s, 4H), 4.32 (s, 2H); 13C NMR (75 MHz, DMSO-d6): δ 167.0, 150.7, 148.9, 142.4, 135.2, 134.8, 131.8, 131.4 (3JC-F = 3.0 Hz),130.8 (2JC-F = 32.8 Hz), 129.1, 127.9, 123.6 (1JC-F = 271.2 Hz), 122.1, 119.8, 118.4, 115.4, 110.8, 37.8. HRMS (ESI-FTMS Mass (m/z): calcd for C25H15Cl2F6N3O2 [M + H]+ = 574.0518, 576.0490, found 574.0509.
Molecules 26 05083 i053
4-[3-[3,5-Bis(trifluoromethyl)phenyl]-4-[(4-bromo-3-chloro-anilino)methyl]pyrazol-1-yl] benzoic acid (21). Light yellow solid; (569 mg, 92%); IR (KBr pellet, cm−1): 3458, 3087, 1704, 1606, 1317, 1278, 1186, 1135; 1H NMR, 300 MHz (DMSO-d6): δ 8.81 (s, 1H), 8.35 (s, 2H), 8.09–8.05 (m, 5H), 7.37 (d, J = 5.7 Hz, 1H), 6.86 (s, 1H), 6.58 (d, J = 8.4 Hz, 1H), 4.25 (s, 2H); 13C NMR (75 MHz, DMSO-d6): δ 167.0, 149.2, 148.8, 142.4, 135.2, 134.0, 133.6, 131.8, 131.4 (3JC-F = 3.1 Hz), 130.8 (2JC-F = 32.7 Hz), 129.1, 127.9, 123.6 (1JC-F = 271.2 Hz), 122.0, 119.9, 118.4, 113.7, 113.5, 106.5, 38.0. HRMS (ESI-FTMS Mass (m/z): calcd for C25H15BrClF6N3O2 [M + H]+ = 618.0013, 619.9993, found 619.9990.
Molecules 26 05083 i054
4-[3-[3,5-Bis(trifluoromethyl)phenyl]-4-[[4-fluoro-3-(trifluoromethyl)anilino]methyl]pyrazol-1-yl] benzoic acid (22). White solid; (508 mg, 86%); IR (KBr pellet, cm−1): 3429, 3093, 1701, 1608, 1422, 1282, 1154; 1H NMR, 300 MHz (DMSO-d6): δ 8.83 (s, 1H), 8.37 (s, 2H), 8.06 (s, 5H), 7.22 (br, 1H), 6.93 (s, 2H), 6.44 (s, 1H), 4.30 (s, 2H); 13C NMR (75 MHz, DMSO-d6): δ 167.0, 152.6 (d, 1JC-F = 249.0 Hz), 148.9, 145.4, 142.45, 135.2, 131.8, 131.4 (3JC-F = 3.8 Hz), 130.8 (2JC-F = 32.7 Hz), 128.9 (2JC-F = 32.4 Hz), 127.9, 123.6 (1JC-F = 271.1 Hz), 122.0 (3JC-F = 3.6 Hz), 123.3 (1JC-F = 270.1 Hz), 120.0, 118.4, 117.9 (d, 2JC-F = 21.1 Hz), 117.5 (d, 3JC-F = 7.2 Hz), 117.0 (dd, JC-F = 13.5, 24.0 Hz), 109.4 (d, 4JC-F = 4.6 Hz), 38.3. HRMS (ESI-FTMS Mass (m/z): calcd for C26H15F10N3O2 [M + H]+ = 592.1077, found 592.1082.
Molecules 26 05083 i055
4-[3-[3,5-Bis(trifluoromethyl)phenyl]-4-[[4-bromo-3-(trifluoromethyl)anilino]methyl]pyrazol-1-yl] benzoic acid (23). White solid; (543 mg, 83%); IR (KBr pellet, cm−1): 3454, 2983, 1682, 1605, 1439, 1278, 1142; 1H NMR, 300 MHz (DMSO-d6): δ 8.83 (s, 1H), 8.36 (s, 2H), 8.11–8.07 (m, 5H), 7.51 (d, J = 8.7 Hz, 1H), 7.08 (s, 1H), 6.93–6.81 (m, 2H), 4.35 (s, 2H); 13C NMR (75 MHz, DMSO-d6): δ 167.0, 148.9, 148.1, 142.4, 135.5 (3JC-F = 29.2 Hz), 131.4 (3JC-F = 4.8 Hz), 130.8 (2JC-F = 32.4 Hz), 129.1, 128.8, 127.9 (3JC-F = 6.1 Hz), 123.6 (1JC-F = 271.1 Hz), 122.1, 120.1, 119.8, 118.5, 117.0, 116.2, 111.9, 103.2, 37.9. HRMS (ESI-FTMS Mass (m/z): calcd for C26H15BrF9N3O2 [M + H]+ = 652.0277, 654.0258, found 652.0280.
Molecules 26 05083 i056
4-[3-[3,5-Bis(trifluoromethyl)phenyl]-4-[(2,3,4-trifluoroanilino)methyl]pyrazol-1-yl] benzoic acid (24). White solid; (433 mg, 77%); IR (KBr pellet, cm−1): 3413, 3090, 1694, 1608, 1359, 1281, 1174, 1131; 1H NMR, 300 MHz (DMSO-d6): δ 8.74 (s, 1H), 8.39 (s, 2H), 8.12–8.06 (m, 5H), 7.07–7.04 (m, 1H), 6.60–6.58 (m, 1H), 6.17 (s, 1H), 4.39 (s, 2H); 13C NMR (75 MHz, DMSO-d6): δ 167.0, 148.8, 142.5, 142.3 (dd, JC-F = 10.9, 239.0 Hz), 140.1 (dt, JC-F = 7.2, 234.3 Hz), 139.6 (d, 1JC-F = 242.7 Hz), 135.5, 134.7 (d, 3JC-F = 9.6 Hz), 131.8, 131.4 (3JC-F = 5.0 Hz), 130.6 (2JC-F = 32.6 Hz), 129.0, 128.1 (d, 4JC-F = 2.7 Hz), 123.6 (1JC-F = 271.1 Hz), 121.9, 120.3, 118.4, 111.8 (dd, JC-F = 3.2, 18.7 Hz), 106.6, 38.3. HRMS (ESI-FTMS Mass (m/z): calcd for C25H14F9N3O2 [M + H]+ = 560.1015, found 560.1030.
Molecules 26 05083 i057
4-[3-[3,5-Bis(trifluoromethyl)phenyl]-4-[(3,4,5-trifluoroanilino)methyl]pyrazol-1-yl] benzoic acid (25). White solid; (427 mg, 76%); IR (KBr pellet, cm−1): 3420, 1689, 1608, 1359, 1279, 1178, 1135; 1H NMR, 300 MHz (DMSO-d6): δ 8.82 (s, 1H), 8.37 (s, 2H), 8.12–8.08 (m, 5H), 6.54 (s, 3H), 4.29 (s, 2H); 13C NMR (75 MHz, DMSO-d6): δ 167.0, 152.0 (dt, J = 10.2, 233.5 Hz), 148.9, 145.5 (t, J = 12.1 Hz), 142.4, 135.2, 132.1 (2JC-F = 38.8 Hz), 131.5, 130.9 (3JC-F = 8.5 Hz), 130.5, 129.2, 127.9, 123.6 (1JC-F = 271.1 Hz), 122.1, 119.7, 118.5, 96.1 (d, 2JC-F = 22.9 Hz), 38.1. HRMS (ESI-FTMS Mass (m/z): calcd for C25H14F9N3O2 [M + H]+ = 560.1015, found 560.1026.
Molecules 26 05083 i058
4-[3-[3,5-Bis(trifluoromethyl)phenyl]-4-[(5-chloro-2,4-difluoro-anilino)methyl] pyraz-ol-1-yl] benzoic acid (26). Light yellow solid; (477 mg, 83%); IR (KBr pellet, cm−1): 3446, 3061, 1682, 1608, 1364, 1277, 1175, 1132; 1H NMR, 300 MHz (DMSO-d6): δ 8.74 (s, 1H), 8.39 (s, 2H), 8.12–8.06 (m, 5H), 7.37 (t, J = 9.2 Hz, 1H), 6.96 (t, J = 8.3 Hz, 1H), 6.11 (s, 1H), 4.38 (d, J = 4.7 Hz, 2H); 13C NMR (75 MHz, DMSO-d6): δ 167.0, 149.3 (dd, JC-F = 10.3, 246.6 Hz), 148.9, 148.3 (dd, JC-F = 11.3, 240.7 Hz), 142.5, 135.4, 134.5 (d, 3JC-F = 10.7 Hz), 131.8, 131.4 (3JC-F = 6.7 Hz), 130.7 (2JC-F = 32.7 Hz), 129.0, 128.1, 123.6 (1JC-F = 271.1 Hz), 120.2, 118.4, 115.0 (d, 2JC-F = 21.6 Hz), 112.6 (m), 105.2 (t, JC-F = 25.0 Hz), 79.4 (t, JC-F = 32.8 Hz), 38.2. HRMS (ESI-FTMS Mass (m/z): calcd for C25H14ClF8N3O2 [M + H]+ = 576.0720, 578.0692, found 576.0721.
Molecules 26 05083 i059
4-[3-[3,5-Bis(trifluoromethyl)phenyl]-4-[(3-chloro-2,4-difluoro-anilino)methyl]pyraz-ol-1-yl] benzoic acid (27). Off white solid; (399 mg, 69%); IR (KBr pellet, cm−1): 3425, 2875, 1694, 1608, 1359, 1278, 1173, 1128; 1H NMR, 300 MHz (DMSO-d6): δ 8.74 (s, 1H), 8.39 (s, 2H), 8.12–8.06 (m, 5H), 7.07 (t, J = 8.9 Hz, 1H), 6.83–6.78 (m, 1H), 6.11 (s, 1H), 4.41 (s, 2H); 13C NMR (75 MHz, DMSO-d6): δ 167.0, 149.6 (d, 1JC-F = 235.9 Hz), 148.8, 147.6 (d, 1JC-F = 244.6 Hz), 142.5, 135.5, 134.3 (d, 3JC–F = 11.1 Hz), 131.8, 131.4 (3JC-F = 7.7 Hz), 130.7 (2JC-F = 25.6 Hz), 129.0, 128.1, 123.6 (1JC-F = 271.1 Hz), 122.0, 120.4, 118.4, 111.7 (d, 2JC-F = 23.1 Hz), 111.0 (d, 4JC-F = 4.6 Hz), 108.5 (d, 2JC-F = 21.5 Hz), 38.3. HRMS (ESI-FTMS Mass (m/z): calcd for C25H14ClF8N3O2 [M + H]+ = 576.0720, 578.0692, found 576.0729.
Molecules 26 05083 i060
4-[3-[3,5-Bis(trifluoromethyl)phenyl]-4-[(3,5-dichloro-4-fluoro-anilino)methyl]pyraz-ol-1-yl] benzoic acid (28). Light yellow solid; (533 mg, 90%); IR (KBr pellet, cm−1): 3409, 3087, 1686, 1607, 1359, 1282, 1187, 1143; 1H NMR, 300 MHz (DMSO-d6): δ 8.81 (s, 1H), 8.36 (s, 2H), 8.12–8.07 (m, 5H), 6.79 (d, J = 5.6 Hz, 2H), 6.49 (s, 1H), 4.30 (d, J = 3.8 Hz, 2H); 13C NMR (75 MHz, DMSO-d6): δ 167.0, 148.8, 146.0, 145.3 (d, 1JC-F = 233.6 Hz), 143.8, 135.2, 131.8, 131.4 (3JC-F = 3.2 Hz), 130.8 (2JC-F = 32.7 Hz), 129.1 (d, 3JC-F = 7.1 Hz), 127.9, 123.6 (1JC-F = 271.2 Hz), 122.0, 121.5 (d, 2JC-F = 17.7 Hz), 119.8, 118.4, 118.2, 112.1, 79.4 (t, JC-F = 33.0 Hz), 38.1. HRMS (ESI-FTMS Mass (m/z): calcd for C25H14Cl2F7N3O2 [M + H]+ = 592.0424, 594.0396, found 592.0402.
Molecules 26 05083 i061
4-[3-[3,5-Bis(trifluoromethyl)phenyl]-4-[(4-bromo-3-chloro-2-fluoro-anilino)methyl]pyrazol-1-yl] benzoic acid (29). Light yellow solid; (558 mg, 88%); IR (KBr pellet, cm−1): 3464, 2860, 1686, 1601, 1424, 1064; 1H NMR, 300 MHz (DMSO-d6): δ 8.72 (s, 1H), 8.37 (s, 2H), 8.14–8.07 (m, 5H), 7.32 (d, J = 8.8 Hz, 1H), 6.75 (t, J = 8.5 Hz, 1H), 6.49 (s, 1H), 4.44 (d, J = 4.5 Hz, 2H); 13C NMR (75 MHz, DMSO-d6): δ 167.0, 148.7, 147.4 (d, 1JC-F = 243.0 Hz), 142.5, 137.2 (d, 3JC-F = 12.0 Hz), 135.5, 131.4, 130.6 (2JC-F = 33.2 Hz), 129.0, 128.7 (3JC-F = 3.0 Hz), 128.1, 123.6 (1JC-F = 271.1 Hz), 122.0, 120.4 (d, 2JC-F = 24.6 Hz), 118.4, 117.1, 112.6, 106.8, 103.2 (t, JC-F = 20.9 Hz), 38.1. HRMS (ESI-FTMS Mass (m/z): calcd for C25H14BrClF7N3O2 [M + H]+ = 635.9919, 637.9899, found 637.9897.
Molecules 26 05083 i062
4-[3-[3,5-Bis(trifluoromethyl)phenyl]-4-[(3,5-dichloro-2,4-difluoro-anilino)methyl]pyrazol-1-yl] benzoic acid (30). Off white solid; (413 mg, 67%); IR (KBr pellet, cm−1): 3427, 3088, 1694, 1608, 1360, 1278, 1178, 1135; 1H NMR, 300 MHz (DMSO-d6): δ 8.72 (s, 1H), 8.36 (s, 2H), 8.12–8.06 (m, 5H), 6.99 (t, J = 7.6 Hz, 1H), 6.45 (d, J = 4.32 Hz, 1H), 4.45 (s, 2H); 13C NMR (75 MHz, DMSO-d6): δ 167.0, 148.8, 145.8 (d, 1JC-F = 243.7 Hz), 144.9 (d, 1JC-F = 235.9 Hz), 142.5, 135.5, 134.6 (dd, JC-F = 7.5, 10.0 Hz), 131.8, 131.4 (d, 3JC-F = 6.1 Hz), 130.6 (2JC-F = 36.8 Hz), 129.0, 128.1, 123.6 (1JC-F = 271.4 Hz), 122.0, 120.2, 118.5, 116.2 (d, 2JC-F = 19.1 Hz), 110.7 (3JC-F = 3.7 Hz), 109.8 (t, JC-F = 19.7 Hz), 38.0. HRMS (ESI-FTMS Mass (m/z): calcd for C25H13Cl2F8N3O2 [M + H]+ = 610.0330, 612.0302, found 610.0322.

3.5. Minimum Inhibitory Concentration Assay (MIC)

As previously reported, the MIC values of the substances were calculated using the standard microdilution technique suggested by the Clinical and Laboratory Standards Institute (CLSI) [36]. Compounds were dissolved in dimethyl sulfoxide (DMSO) to achieve a starting concentration of 32 µg/mL as described by us previously [29,31]. Compounds were further diluted two-fold across the 96-well honeycomb plate columns in cation adjusted Mueller Hinton broth (CAMHB), and bacterial culture was added. Plates were incubated for 18–20 h at 35 ℃ before determining the minimum concentrations at which wells had no visible turbidity to the naked eye. The MIC values were determined from at least a duplicate result obtained from three independent experiments using fresh bacterial cultures on different days.

3.6. Cytotoxicity Assay

The human embryonic kidney cell line (HEK-293) was used to assess the cytotoxicity of the antibiotics as described by us previously [29,31]. HEK-293 cells were cultured in Dulbecco’s modified eagle’s medium (DMEM) containing 10% Fetal Bovine Serum (FBS) and incubated at 37 °C in the presence of 5% carbon dioxide. HEK-293 cells were cultured in 96-well black plates with 6000 cells per well for the first 24 h followed by treatment with a range of concentrations of antibiotics dissolved in DMSO for the next 24 h. After the second period of incubation, resazurin (40 µL of 0.15 mg/mL) was added to each well and incubated for an additional 4 h. Reduction of resazurin was measured fluorometrically with excitation wavelength at 560 nm and emission at 590 nm using BioTek™ Cytation™5 plate reader. Percentage viability of HEK cells for each range of concentrations was calculated, taking the fluorescence value of the wells treated with DMSO as a reference, using Microsoft® Excel® for Office 365 MSO. IC50 values were computed using the calculated percentage viability values through data processing in Graphpad Prism 7 for Windows, Version 7.04.

3.7. Time Kill Assay

Time Kill Assay was performed against S. aureus ATCC 33599 using our potent compounds following methodology reported previously with few modifications [29,31]. The bacterial strain was grown to its logarithmic growth phase by shaking at 200 rpm in a shaking incubator at 35 °C. The culture was diluted to ~1.5 × 107 CFU/mL in CAMHB and treated with concentrations equivalent to 4× MIC of tested compounds, including vancomycin and daptomycin, as control drugs. Aliquots were collected from treatment every two hours of incubation at 35 °C up to 12 h and one in 24 h, then serially diluted in sterile 1× PBS. The diluted aliquots were then transferred to blood agar plates by using the 6 × 6 drop plate method and incubated at 35 °C for 18–20 h prior to colony counting to obtain CFU/mL. Time-kill line graphs (CFU/mL vs. time) were constructed using Microsoft® Excel® for Office 365 MSO.

3.8. Persister Assay

The persister assay was performed following the methodology described previously [29]. Briefly, for persister viability assays, S. aureus ATCC 700699 strain (MRSA) was grown to stationary phase in CAMHB medium by shaking at 200 rpm in a shaking incubator for 24 h at 35 °C. An aliquot of stationary phase culture was washed and diluted to ~5 × 108 CFU/mL in 1×PBS then treated with 32× MIC of each compound and control drugs in sterile 10 × 75 mm plastic culture tubes and incubated at 35 °C with shaking at 200 rpm for 4 h. After incubation, 400 µL aliquot was washed, serially diluted in PBS, and plated in blood agar plate for viable colony count.
Likewise, for persister time-kill assays, the persister cells were treated at varied concentrations and incubated with shaking. At the start and every 2 h until 8 h, 400 µL samples were washed, serially diluted, and plated on blood agar using the 6 × 6 drop plate method. Plates were incubated for 18–20 h at 35 °C, before the colonies were counted to calculate CFU/mL. All the treatments were performed in triplicates.

3.9. Calgary Biofilm Device

Minimum biofilm eradication concentration (MBEC) was determined using a Calgary device using the protocol reported elsewhere with some modifications [37]. The Calgary device is a 96-well plate with a lid containing pegs to establish biofilms. Bacteria from an overnight plate culture were suspended to a 0.5 McFarland turbidity, then diluted 1:100 in a CAMHB containing 1% glucose which was inoculated in the 96 wells (150 μL in each well) and incubated at 35 °C for 24 h to establish biofilm on the pegs. The lid was then removed, washed with PBS in a fresh 96 well plate, then transferred to another 96-well plate containing 2-fold serial dilutions of the test compounds dissolved in PBS (150 μL total volume in each well). This plate was called the “challenge plate”. The challenge plate was incubated for an additional 24 h, and the lid was transferred to the next 96-well plate containing fresh CAMHB media with 1% glucose (180 μL) and further incubated for 24 h. After this final incubation, the wells were observed for visible turbidity. MBEC was the well with the lowest concentration of compound that resulted in no turbidity. All the compounds were tested in a minimum of three independent experiments.

4. Conclusions

In summary, we are reporting an efficient synthesis of 30 novel pyrazole derivatives. Most of these compounds are potent growth inhibitors of Gram-positive bacterial strains with MIC values as low as 0.25 µg/mL. These bactericidal compounds are potent against MRSA persisters. Three of the four compounds tested for their biofilm eradication property showed potent activity. Enthusiasm was a little bit dampened, due to the toxicity of the compounds for human cell lines. Nevertheless, these potent compounds can be modified to increase their pharmacological properties and reduce their toxicity profile.

Supplementary Materials

Figure S1–S31: Characterization data (I-B).

Author Contributions

I.S.A., H.R.K., M.K.A.-g., and S.R.—methodology, investigation, and validation; M.A.A.—conceptualization, project administration, manuscript writing—original draft and supervision; D.F.G.—supervision and manuscript editing. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by Arkansas INBRE P20 GM103429 and the Kays Foundation grant. ABI provided different resources to accomplish the project.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Acknowledgments

This manuscript was made possible by the Arkansas INBRE Summer Research Grant, supported by a grant from the National Institute of General Medical Sciences, (NIGMS), P20 GM103429, from the National Institutes of Health. The Research Technology Core of the Arkansas INBRE program, supported by a grant from the National Institute of General Medical Sciences, (NIGMS), P20 GM103429, from the National Institutes of Health, was helpful to get HRMS data. The Kays Foundation grant was the key to completing antimicrobial studies. We are thankful to the Department of Chemistry and Physics, and Arkansas Biosciences Institute at the Arkansas State University for providing infrastructure and support.

Conflicts of Interest

The authors declare no conflict of interest.

Sample Availability

Samples of the compounds (1–30) are available from the authors.

References

  1. Oliveira, D.M.P.D.; Forde, B.M.; Kidd, T.J.; Harris, P.N.A.; Schembri, M.A.; Beatson, S.A.; Paterson, D.L.; Walker, M.J. Antimicrobial Resistance in ESKAPE Pathogens. Clin. Microbiol. Rev. 2020, 33, e00181-19. [Google Scholar] [CrossRef] [PubMed]
  2. Agudelo Higuita, N.I.; Huycke, M.M. Enterococcal Disease, Epidemiology, and Implications for Treatment. In Enterococci: From Commensals to Leading Causes of Drug Resistant Infection; Gilmore, M.S., Clewell, D.B., Ike, Y., Shankar, N., Eds.; Massachusetts Eye and Ear Infirmary: Boston, MA, USA, 2014. [Google Scholar]
  3. CDC Vancomycin-Resistant Enterococci (VRE). Available online: https://www.cdc.gov/drugresistance/pdf/threats-report/vre-508.pdf (accessed on 23 May 2020).
  4. Ch’ng, J.-H.; Chong, K.K.L.; Lam, L.N.; Wong, J.J.; Kline, K.A. Biofilm-Associated Infection by Enterococci. Nat. Rev. Microbiol. 2019, 17, 82–94. [Google Scholar] [CrossRef] [PubMed]
  5. Pidot, S.J.; Gao, W.; Buultjens, A.H.; Monk, I.R.; Guerillot, R.; Carter, G.P.; Lee, J.Y.H.; Lam, M.M.C.; Grayson, M.L.; Ballard, S.A.; et al. Increasing Tolerance of Hospital Enterococcus Faecium to Handwash Alcohols. Sci. Transl. Med. 2018, 10, eaar6115. [Google Scholar] [CrossRef] [Green Version]
  6. CDC General Information about Staphylococcus Aureus. Available online: https://www.cdc.gov/hai/organisms/staph.html (accessed on 15 July 2021).
  7. Craft, K.M.; Nguyen, J.M.; Berg, L.J.; Townsend, S.D. Methicillin-Resistant Staphylococcus Aureus (MRSA): Antibiotic-Resistance and the Biofilm Phenotype. Medchemcomm 2019, 10, 1231–1241. [Google Scholar] [CrossRef]
  8. Mistry, T.L.; Truong, L.; Ghosh, A.K.; Johnson, M.E.; Mehboob, S. Benzimidazole-Based FabI Inhibitors: A Promising Novel Scaffold for Anti-staphylococcal Drug Development. ACS Infect. Dis. 2017, 3, 54–61. [Google Scholar] [CrossRef] [Green Version]
  9. Moisse, K. Antibiotic Resistance Could Bring ‘End of Modern Medicine’. Available online: http://abcnews.go.com/blogs/health/2012/03/16/antibiotic-resistance-could-bring-end-of-modern-medicine/ (accessed on 1 May 2020).
  10. Naim, M.J.; Alam, O.; Nawaz, F.; Alam, M.J.; Alam, P. Current Status of Pyrazole and Its Biological Activities. J. Pharm. Bioallied. Sci. 2016, 8, 2–17. [Google Scholar]
  11. Steinbach, G.; Lynch, P.M.; Phillips, R.K.S.; Wallace, M.H.; Hawk, E.; Gordon, G.B.; Wakabayashi, N.; Saunders, B.; Shen, Y.; Fujimura, T.; et al. The Effect of Celecoxib, a Cyclooxygenase-2 Inhibitor, in Familial Adenomatous Polyposis. N. Engl. J. Med. 2000, 342, 1946–1952. [Google Scholar] [CrossRef]
  12. Hampp, C.; Hartzema, A.G.; Kauf, T.L. Cost-Utility Analysis of Rimonabant in the Treatment of Obesity. Value Health 2008, 11, 389–399. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  13. Kameyama, T.; Nabeshima, T. Effects of 1,3-Diphenyl-5-(2-Dimethylaminopropionamide)-Pyrazole[Difenamizole] on a Conditioned Avoidance-Response. Neuropharmacology 1978, 17, 249–256. [Google Scholar] [PubMed]
  14. Dalvie, D.K.; Kalgutkar, A.S.; Khojasteh-Bakht, S.C.; Obach, R.S.; O’Donnell, J.P. Biotransformation Reactions of Five-Membered Aromatic Heterocyclic Rings. Chem. Res. Toxicol. 2002, 15, 269–299. [Google Scholar] [CrossRef] [PubMed]
  15. Chen, L.W.; Wang, P.F.; Tang, D.J.; Tao, X.X.; Man, R.J.; Qiu, H.Y.; Wang, Z.C.; Xu, C.; Zhu, H.L. Metronidazole Containing Pyrazole Derivatives Potently Inhibit Tyrosyl-tRNA Synthetase: Design, Synthesis, and Biological Evaluation. Chem. Biol. Drug. Des. 2016, 88, 592–598. [Google Scholar] [CrossRef]
  16. Hafez, H.N.; El-Gazzar, A.R.; Al-Hussain, S.A. Novel Pyrazole Derivatives with Oxa/Thiadiazolyl, Pyrazolyl Moieties and Pyrazolo [4,3-d]-Pyrimidine Derivatives as Potential Antimicrobial and Anticancer Agents. Bioorg. Med. Chem. Lett. 2016, 26, 2428–2433. [Google Scholar] [CrossRef] [PubMed]
  17. Nayak, N.; Ramprasad, J.; Dalimba, U. New INH-Pyrazole Analogs: Design, Synthesis and Evaluation of Antitubercular and Antibacterial Activity. Bioorg. Med. Chem. Lett. 2015, 25, 5540–5545. [Google Scholar] [CrossRef]
  18. Allison, D.; Delancey, E.; Ramey, H.; Williams, C.; Alsharif, Z.A.; Al-khattabi, H.; Ontko, A.; Gilmore, D.; Alam, M.A. Synthesis and Antimicrobial Studies of Novel Derivatives of 4-(4-formyl-3-phenyl-1H-pyrazol-1-yl)Benzoic Acid as Potent Anti-Acinetobacter Baumannii Agents. Bioorg. Med. Chem. Lett. 2017, 27, 387–392. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  19. Zakeyah, A.A.; Whitt, J.; Duke, C.; Gilmore, D.F.; Meeker, D.G.; Smeltzer, M.S.; Alam, M.A. Synthesis and Antimicrobial Studies of Hydrazone Derivatives of 4-[3-(2,4-Difluorophenyl)-4-formyl-1H-pyrazol-1-yl]benzoic acid and 4-[3-(3,4-difluorophenyl)-4-formyl-1H-Pyrazol-1-yl]Benzoic Acid. Bioorg. Med. Chem. Lett. 2018, 28, 2914–2919. [Google Scholar] [CrossRef] [PubMed]
  20. Whitt, J.; Duke, C.; Sumlin, A.; Chambers, S.A.; Alnufaie, R.; Gilmore, D.; Fite, T.; Basnakian, A.G.; Alam, M.A. Synthesis of Hydrazone Derivatives of 4-[4-Formyl-3-(2-oxochromen-3-yl)pyrazol-1-yl]Benzoic acid as Potent Growth Inhibitors of Antibiotic-Resistant Staphylococcus Aureus and Acinetobacter Baumannii. Molecules 2019, 24, 2051. [Google Scholar] [CrossRef] [Green Version]
  21. Brider, J.; Rowe, T.; Gibler, D.J.; Gottsponer, A.; Delancey, E.; Branscum, M.D.; Ontko, A.; Gilmore, D.; Alam, M.A. Synthesis and antimicrobial studies of azomethine and N-arylamine derivatives of 4-(4-formyl-3-phenyl-1H-pyrazol-1-yl)Benzoic Acid as Potent Anti-Methicillin-Resistant Staphylococcus Aureus Agents. Med. Chem. Res. 2016, 25, 2691–2697. [Google Scholar] [CrossRef]
  22. Whitt, J.; Duke, C.; Ali, M.A.; Chambers, S.A.; Khan, M.M.K.; Gilmore, D.; Alam, M.A. Synthesis and Antimicrobial Studies of 4-[3-(3-Fluorophenyl)-4-formyl-1H-Pyrazol-1-yl]Benzoic Acid and 4-[3-(4-Fluorophenyl)-4-formyl-1H-pyrazol-1-yl]benzoic Acid as Potent Growth Inhibitors of Drug-Resistant Bacteria. ACS Omega 2019, 4, 14284–14293. [Google Scholar] [CrossRef] [Green Version]
  23. Ahn, M.; Gunasekaran, P.; Rajasekaran, G.; Kim, E.Y.; Lee, S.-J.; Bang, G.; Cho, K.; Hyun, J.-K.; Lee, H.-J.; Jeon, Y.H.; et al. Pyrazole Derived Ultra-Short Antimicrobial Peptidomimetics with Potent Anti-Biofilm Activity. Eur. J. Med. Chem. 2017, 125, 551–564. [Google Scholar] [CrossRef]
  24. Khan, M.F.; Alam, M.M.; Verma, G.; Akhtar, W.; Akhter, M.; Shaquiquzzaman, M. The Therapeutic Voyage of Pyrazole and its Analogs: A Review. Eur. J. Med. Chem. 2016, 120, 170–201. [Google Scholar] [CrossRef]
  25. Sidhartha, S.K.; Cinu, A.T. Strategically Placed Trifluoromethyl Substituent in the Realm of Antitubercular Drug Design. Curr. Drug Ther. 2019, 14, 114–123. [Google Scholar]
  26. Keam, S.J.; Scott, L.J. Dutasteride: A Review of its Use in the Management of Prostate Disorders. Drugs 2008, 68, 463–485. [Google Scholar] [CrossRef]
  27. Shang, Z.; Li, Y.; Zhang, M.; Tian, J.; Han, R.; Shyr, C.R.; Messing, E.; Yeh, S.; Niu, Y.; Chang, C. Antiandrogen Therapy with Hydroxyflutamide or Androgen Receptor Degradation Enhancer ASC-J9 Enhances BCG Efficacy to Better Suppress Bladder Cancer Progression. Mol. Cancer Ther. 2015, 14, 2586–2594. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  28. Junaid, Z.; Patel, J. Cinacalcet; StatPearls: Treasure Island, FL, USA, 2021. [Google Scholar]
  29. Hansa, R.K.C.; Khan, M.M.K.; Frangie, M.M.; Gilmore, D.F.; Shelton, R.S.; Savenka, A.V.; Basnakian, A.G.; Shuttleworth, S.L.; Smeltzer, M.S.; Alam, M.A. 4-4-(Anilinomethyl)-3-[4-(trifluoromethyl)phenyl]-1H-Pyrazol-1-Ylbenzoic Acid Derivatives as Potent Anti-Gram-Positive Bacterial Agents. Eur. J. Med. Chem. 2021, 219, 113402. [Google Scholar] [CrossRef]
  30. Alnufaie, R.; Kc, H.R.; Alsup, N.; Whitt, J.; Chambers, S.A.; Gilmore, D.; Alam, M.A. Synthesis and Antimicrobial Studies of Coumarin-Substituted Pyrazole Derivatives as Potent Anti-Staphylococcus Aureus Agents. Molecules 2020, 25, 2758. [Google Scholar] [CrossRef]
  31. Alnufaie, R.; Alsup, N.; Kc, H.R.; Newman, M.; Whitt, J.; Chambers, S.A.; Gilmore, D.; Alam, M.A. Design and Synthesis of 4-[4-formyl-3-(2-naphthyl)pyrazol-1-yl]benzoic Acid Derivatives as Potent Growth Inhibitors of Drug-Resistant Staphylococcus aureus. J. Antibiot. 2020, 73, 818–827. [Google Scholar] [CrossRef]
  32. Delancey, E.; Allison, D.; KC, H.R.; Gilmore, D.F.; Fite, T.; Basnakian, A.G.; Alam, M.A. Synthesis of 4,4-(4-Formyl-1H-pyrazole-1,3-diyl)dibenzoic Acid Derivatives as Narrow Spectrum Antibiotics for the Potential Treatment of Acinetobacter Baumannii Infections. Antibiotics 2020, 9, 650. [Google Scholar] [CrossRef]
  33. Scheper, H.; Wubbolts, J.M.; Verhagen, J.A.M.; de Visser, A.W.; van der Wal, R.J.P.; Visser, L.G.; de Boer, M.G.J.; Nibbering, P.H. SAAP-148 Eradicates MRSA Persisters Within Mature Biofilm Models Simulating Prosthetic Joint Infection. Front. Microbiol. 2021, 12, 625952. [Google Scholar] [CrossRef] [PubMed]
  34. Kim, W.; Zou, G.; Hari, T.P.A.; Wilt, I.K.; Zhu, W.; Galle, N.; Faizi, H.A.; Hendricks, G.L.; Tori, K.; Pan, W.; et al. A Selective Membrane-Targeting Repurposed Antibiotic with Activity against Persistent Methicillin-resistantstaphylococcus Aureus. Proc. Natl. Acad. Sci. USA 2019, 116, 16529–16534. [Google Scholar] [CrossRef] [Green Version]
  35. Kim, W.; Zhu, W.; Hendricks, G.L.; Van Tyne, D.; Steele, A.D.; Keohane, C.E.; Fricke, N.; Conery, A.L.; Shen, S.; Pan, W.; et al. A New Class of Synthetic Retinoid Antibiotics Effective against Bacterial Persisters. Nature 2018, 556, 103–107. [Google Scholar] [CrossRef]
  36. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically. CLSI Approved Standards M7-A11. Clinical and Laboratory Standards Institute, Wayne, 2018. Available online: https://clsi.org/media/1928/m07ed11_sample.pdf (accessed on 26 March 2020).
  37. Garrison, A.T.; Abouelhassan, Y.; Kallifidas, D.; Tan, H.; Kim, Y.S.; Jin, S.; Luesch, H.; Huigens, R.W. An Efficient Buchwald–Hartwig/Reductive Cyclization for the Scaffold Diversification of Halogenated Phenazines: Potent Antibacterial Targeting, Biofilm Eradication, and Prodrug Exploration. J. Med. Chem. 2018, 61, 3962–3983. [Google Scholar] [CrossRef] [PubMed]
Molecules 26 05083 g001 550
Figure 1. Representative examples of trifluoromethyl phenyl-containing approved drugs.
Figure 1. Representative examples of trifluoromethyl phenyl-containing approved drugs.
Molecules 26 05083 g001
Molecules 26 05083 g002 550
Figure 2. Cytotoxicity of potent antimicrobials for human embryonic kidney (HEK-293) cells. The data show the average of the IC50 values obtained from triplicate assays for each compound. Error bars indicate the standard deviation values (n = 3).
Figure 2. Cytotoxicity of potent antimicrobials for human embryonic kidney (HEK-293) cells. The data show the average of the IC50 values obtained from triplicate assays for each compound. Error bars indicate the standard deviation values (n = 3).
Molecules 26 05083 g002
Molecules 26 05083 g003 550
Figure 3. Time Kill Assay of potent compounds 5, 11, 28, and 29 against an MRSA (S. aureus ATCC 700699), Vancomycin (V), and Daptomycin (D) are positive controls. All compounds, including positive controls, were tested at a 4× MIC concentration.
Figure 3. Time Kill Assay of potent compounds 5, 11, 28, and 29 against an MRSA (S. aureus ATCC 700699), Vancomycin (V), and Daptomycin (D) are positive controls. All compounds, including positive controls, were tested at a 4× MIC concentration.
Molecules 26 05083 g003
Molecules 26 05083 g004 550
Figure 4. The activity of potent compounds against MRSA persisters. (a) Persister viability assay at 32× MIC for each compound run for 4 h. Persister Time Kill Assay against (b) compound 11 and (c) compound 29 at various MIC values run for 8 h. The error bars represent the standard deviation of the colony count performed in triplicates for each treatment, n = 3.
Figure 4. The activity of potent compounds against MRSA persisters. (a) Persister viability assay at 32× MIC for each compound run for 4 h. Persister Time Kill Assay against (b) compound 11 and (c) compound 29 at various MIC values run for 8 h. The error bars represent the standard deviation of the colony count performed in triplicates for each treatment, n = 3.
Molecules 26 05083 g004
Table
Table 1. Synthesis of 3,5-bis(trifluoromethylphenyl)-derived pyrazole anilines.
Table 1. Synthesis of 3,5-bis(trifluoromethylphenyl)-derived pyrazole anilines.
Molecules 26 05083 i001
#RHRMS
(M + H)+		Yield (%)#RHRMS
(M + H)+		Yield (%)
1 Molecules 26 05083 i002506.12918616 Molecules 26 05083 i003598.055382
2 Molecules 26 05083 i004548.17618017 Molecules 26 05083 i005542.112283
3 Molecules 26 05083 i006562.19199318 Molecules 26 05083 i007558.081690
4 Molecules 26 05083 i008536.13977719 Molecules 26 05083 i009560.077686
5 Molecules 26 05083 i010598.15567920 Molecules 26 05083 i011574.050985
6 Molecules 26 05083 i012552.11737021 Molecules 26 05083 i013619.999092
7 Molecules 26 05083 i014524.12088222 Molecules 26 05083 i015592.108286
8 Molecules 26 05083 i016524.12008423 Molecules 26 05083 i017652.028083
9 Molecules 26 05083 i018540.09077224 Molecules 26 05083 i019560.103077
10 Molecules 26 05083 i020584.04108525 Molecules 26 05083 i021560.102676
11 Molecules 26 05083 i022584.04087826 Molecules 26 05083 i023576.072183
12 Molecules 26 05083 i024550.11948327 Molecules 26 05083 i025576.072969
13 Molecules 26 05083 i026550.11978228 Molecules 26 05083 i027592.040290
14 Molecules 26 05083 i028538.13569229 Molecules 26 05083 i029637.989788
15 Molecules 26 05083 i030554.10658130 Molecules 26 05083 i031610.032267
Table
Table 2. MIC (µg/mL) data of the synthesized compounds. Gram-positive: Antibiotic susceptible S. aureus ATCC 25923 (Sa23), antibiotic-resistant (methicillin-resistant) strains: S. aureus BAA-2312 (Sa12), S. aureus ATCC 33591 (Sa91), S. aureus ATCC 33592 (Sa92), and S. aureus ATCC 700699 (Sa99); S. epidermidis ATCC 700296 (Se), antibiotic susceptible E. faecalis ATCC 29212 (Ef12), antibiotic-resistant (vancomycin-resistant, VRE) E. faecalis ATCC 51299 (Ef99), antibiotic-resistant (vancomycin-resistant, VRE) E. faecium ATCC 700221 (Ef21), Bacillus subtilis ATCC 6623 (Bs), V = Vancomycin and D = Daptomycin, n = 3.
Table 2. MIC (µg/mL) data of the synthesized compounds. Gram-positive: Antibiotic susceptible S. aureus ATCC 25923 (Sa23), antibiotic-resistant (methicillin-resistant) strains: S. aureus BAA-2312 (Sa12), S. aureus ATCC 33591 (Sa91), S. aureus ATCC 33592 (Sa92), and S. aureus ATCC 700699 (Sa99); S. epidermidis ATCC 700296 (Se), antibiotic susceptible E. faecalis ATCC 29212 (Ef12), antibiotic-resistant (vancomycin-resistant, VRE) E. faecalis ATCC 51299 (Ef99), antibiotic-resistant (vancomycin-resistant, VRE) E. faecium ATCC 700221 (Ef21), Bacillus subtilis ATCC 6623 (Bs), V = Vancomycin and D = Daptomycin, n = 3.
#Sa23Sa12Sa91Sa92Sa99SeEf12Ef99Ef21Bs
14244488442
22111222111
311122110.522
48488816161684
51211242112
62222444221
74242448442
82222444441
92121222221
102222244242
112111222111
12>32>32>32>32>32>32>32>32>32>32
13>3232>32>32>32>32>32>32>32>32
142121242211
152112222211
161111221211
172222244421
182111222211
1910.50.51211111
20110.51121111
21110.50.5221111
221111122212
231211242221
242111242211
254222444421
2620.252114120.250.25
271111222211
281111122211
292111222212
301211222211
V10.522422>32>320.25
D2222821616162
Table
Table 3. Biofilm studies of potent compounds.
Table 3. Biofilm studies of potent compounds.
#MBEC (µg/mL)
Sa23Efs12
5>32>32
1124
2812
2922
V>32>32
D>32>32
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Alkhaibari, I.S.; KC, H.R.; Roy, S.; Abu-gazleh, M.K.; Gilmore, D.F.; Alam, M.A. Synthesis of 3,5-Bis(trifluoromethyl)phenyl-Substituted Pyrazole Derivatives as Potent Growth Inhibitors of Drug-Resistant Bacteria. Molecules 2021, 26, 5083. https://doi.org/10.3390/molecules26165083

AMA Style

Alkhaibari IS, KC HR, Roy S, Abu-gazleh MK, Gilmore DF, Alam MA. Synthesis of 3,5-Bis(trifluoromethyl)phenyl-Substituted Pyrazole Derivatives as Potent Growth Inhibitors of Drug-Resistant Bacteria. Molecules. 2021; 26(16):5083. https://doi.org/10.3390/molecules26165083

Chicago/Turabian Style

Alkhaibari, Ibrahim S., Hansa Raj KC, Subrata Roy, Mohd. K. Abu-gazleh, David F. Gilmore, and Mohammad A. Alam. 2021. "Synthesis of 3,5-Bis(trifluoromethyl)phenyl-Substituted Pyrazole Derivatives as Potent Growth Inhibitors of Drug-Resistant Bacteria" Molecules 26, no. 16: 5083. https://doi.org/10.3390/molecules26165083

Article Metrics

Back to TopTop